Trial intelligence / Profile preview

Imiquimod 3.75% imaging study for subclinical actinic keratosis lesions

2013-004037-32Phase 4Active

Sponsor: Fundació Clínic per a la Recerca Biomèdica
Start: Feb 2014
Modality: Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries: 1

Overview

Phase 4, open-label, single-arm trial of imiquimod in actinic keratosis (AK), sponsored by Fundació Clínic per a la Recerca Biomèdica. Primary endpoint: Subclinical lesions becoming clinically visible and clearing by week 14. Started Feb 2014; status: active.

Drugs

imiquimod

Conditions

actinic keratosis (AK)

Beyond the preview

Go deeper on 2013-004037-32.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2013-004037-32.